Moderna, Inc. (MRNA)

Can Moderna Keep the Beat Streak Alive This Earnings Season?

When MRNA reports first-quarter earnings, investors will likely focus on pipeline updates.

Where Will Moderna Be in 5 Years?

In the early days of the COVID-19 pandemic, Moderna (MRNA -1.89%) was a top performer, from both a share-price and an earnings perspective. As one of the leading coronavirus vaccine companies, the biotech brought in billions of dollars in annual earnings and saw its stock price jump more than 2,300% from January 2020 through early August of 2021.

Vaccine Stocks Rise on Growing Threat of Bird Flu Infections

The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) and Pfizer (PFE) to develop bird flu vaccines over increasing fears of widespread transmission of the infection.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

FDA News Just Shook Moderna. Is the Stock One to Avoid or a Bad-News Buy?

Moderna (MRNA 2.21%) has gone through its share of ups and downs in recent years, from posting soaring coronavirus vaccine revenue a few years ago to seeing demand for that product sink in the later stages of the coronavirus pandemic. Now, the biotech is trying to show the world that it can expand beyond coronavirus prevention as it has a full pipeline of programs ranging from latent viruses and rare diseases to cancer.

Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks

Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'

Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views

Stocks of major vaccine makers dropped on Monday after the Food and Drug Administration's (FDA) top vaccine official Dr. Peter Marks resigned, citing conflicts with Health and Human Services (HHS) Secretary Robert F. Kennedy (RFK) Jr. over his views on immunization.

Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard

Biotech investors are grappling with fresh uncertainty following the abrupt resignation of Dr. Peter Marks, a key figure in the US Food and Drug Administration.

Why Moderna Stock Is Plummeting Today

Shares of Moderna (MRNA -9.35%) are falling on Monday. The company's stock lost 7.9% as of 1:30 p.m.

4 Things You Need to Know if You Buy Moderna Stock Today

It's been nearly five years since Moderna (MRNA -1.60%) emerged as a biotech industry disruptor, with its COVID-19 vaccine playing a landmark role in tackling the global pandemic in late 2020. Despite its generating record sales and profits through 2022, early projections of sustained demand for coronavirus vaccinations failed to materialize, leading to a sharp drop in the business.

Moderna Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?

Given the uncertainty around its top-line growth, short-term investors should exercise caution when investing in MRNA stock.

Why Moderna Stock Has Surged 20% This Week Despite Mixed News

Moderna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open market. The post Why Moderna Stock Has Surged 20% This Week Despite Mixed News appeared first on Investor's Business Daily.

Moderna, Inc. (MRNA) TD Cowen 45th Annual Health Care Conference

Moderna, Inc. (NASDAQ:MRNA ) TD Cowen 45th Annual Health Care Conference March 5, 2025 9:10 AM ET Corporate Participants Stephen Hoge - President Conference Call Participants Tyler Van Buren - TD Cowen Tyler Van Buren All right, well, good morning, everyone. Tyler Van Buren here, Senior Biotech Analyst at TD Cowen.

3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.

Investors looking for growth in recent times have piled into stocks in artificial intelligence and quantum computing. But these aren't the only areas that offer the potential for explosive revenue growth and stock performance.

Everest Medicines to Hold Investor Calls with Updates on mRNA Therapeutic Vaccine Programs

SHANGHAI , Feb. 28, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines, today announced that it will hold investor calls to discuss recent developments on its mRNA therapeutic vaccine programs. The English session of the conference call will be held at 9:00 pm on March 6, 2025 Beijing Time (8:00 am U.S. Eastern Time on March 6), and the Mandarin session of the conference call will be held at 9:00 am Beijing Time on March 7, 2025 (8:00 pm U.S. Eastern Time …

Moderna Tumbles As RFK Jr. Reportedly Mulls Pulling $590 Million In Bird Flu Funds

Moderna stock toppled Thursday on reports the Trump administration is considering pulling bird flu vaccine funding. The post Moderna Tumbles As RFK Jr. Reportedly Mulls Pulling $590 Million In Bird Flu Funds appeared first on Investor's Business Daily.

Trump administration weighs pulling funding for Moderna bird flu vaccine, Bloomberg News reports

U.S. health officials are reevaluating a $590 million contract that was awarded to Moderna for the development of its bird flu vaccine, Bloomberg News reported on Wednesday, citing sources.

SK bioscience Initiates Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate

SK bioscience's first mRNA vaccine candidate enters Phase 1/2 clinical trials in Australia and New Zealand, with interim results expected by 2026 Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding support from CEPI SK bioscience will expand its vaccine portfolio and secure global competitiveness by developing mRNA vaccines SEONGNAM, South Korea , Feb. 25, 2025 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced the commencement of global Phase 1/2 clinical trials for its mRNA-based Japanese encephalitis vaccine candidate, …

Moderna to Present at Upcoming Conferences in March 2025

CAMBRIDGE, MA / ACCESS Newswire / February 25, 2025 / Moderna, Inc. (Nasdaq: MRNA), today announced its participation in the following upcoming investor conferences: TD Cowen 45th Annual Health Care Conference, on Wednesday, March 5th at 9:10am ET Barclays 27th Annual Global Healthcare Conference, on Tuesday, March 11th at 1:30pm ET A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website. Webcast: investors.modernatx.com.

CancerVax Announces Successful Tests of its Smart mRNA Technology

Recent in-vitro lab results confirm that the Company's proprietary Smart mRNA can be used as a potential on/off switch for selectively detecting cancer cells Recent in-vitro lab results confirm that the Company's proprietary Smart mRNA can be used as a potential on/off switch for selectively detecting cancer cells

Moderna and Other Vaccine Stocks Climb After Coronavirus News From China

Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday.

3 Biotech/Healthcare Names Under $10 I Am Buying Now

Today, I am highlighting three biotech/healthcare stocks that currently trade under $10 a share after some recent weakness. ! am slowly accumulating each of these names on these dips both straight equity purchases and covered call orders. All have had some recent positive despite the action in the shares and have good longer-term prospects.

Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So.

In the dark days of the coronavirus pandemic, Moderna (MRNA 0.42%) was a ray of light in more ways than one. The healthcare company's innovative Spikevax was one of the go-to vaccines that sped to market, not only protecting hundreds of millions of people from COVID-19, but also producing gobs of revenue and healthy profits.

Moderna: A Generational Opportunity for Investors in 2025

As bad as it may look on the charts, Moderna's NASDAQ: MRNA post-COVID let-down and market reset are over. The company stock trades at rock bottom in early 2025 and presents a generational opportunity in cutting-edge biotech.

Moderna shares move higher as investors look beyond Q4 losses to pipeline potential

Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares added more than 8% during Tuesday's session as investors remained optimistic about the company's long-term strategy following mixed fourth quarter earnings. The company last week reported a wider-than-expected loss for Q4, as revenue surpassed expectations.

Analyst Confident In Moderna's Cancer Vaccine But Highlights Other Challenges

On Friday, Moderna Inc. MRNA reported a fourth-quarter EPS loss of $(2.91), missing the consensus of $(2.62), a turnaround from EPS income of $0.55 a year ago.

A lot of concern around Moderna over next year or so, says Jefferies Michael Yee

Michael Yee, Jefferies senior analyst, joins 'Closing Bell Overtime' to talk Moderna Q4 results.

Movers: Roku, Moderna, GameStop, Palo Alto

Moderna, Inc.: Working Hard But Competition Is Working Harder

MRNA's stock surged 4,211% during COVID-19 but has since plummeted to $31, reflecting a significant bubble and raising concerns about its future. Declining revenue and net income, driven by reduced COVID-19 vaccine demand and RSV market challenges, highlight MRNA's financial instability. MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and faces tough competition.

Moderna Q4 Earnings and Revenues Beat, COVID Vaccine Sales Decline

MRNA's earnings and revenues surpass estimates in the fourth quarter of 2024. The company reiterates 2025 total revenue guidance.